The Clinical Scholars Program at H. Lee Moffitt Cancer Center and Research Institute provides advanced training for medical and surgical oncology fellows. The overall goal of the Clinical Scholars Programs is to develop clinical investigators. There are two tracks within the Clinical Scholars Program, a clinical investigator track and a translational investigator track, both aimed at facilitating translational cancer research. Each track has two components consisting of didactic training as well as clinical research training in focused areas of cancer research. The didactic component of the Clinical investigator track provides a formal and applied experience in clinical research methods culminating in a Master?s of Science degree in Public Health. Didactic training programs in graduate level courses in molecular biology and immunology are individually tailored for the needs of Clinical Scholars electing the translational investigator track. Clinical rotations in Experimental Therapeutics are required for all Clinical Scholars including the Phase I/II Clinical Research Unit, Clinical Pharmacology, and Translational Research Laboratory. Clinical Research training is focused on three areas: Experimental Therapeutics, Geriatric Oncology, and Health Outcomes Research. The Experimental Therapeutics program links hypothesis-driven research focused on molecular mechanisms of disease pathogenesis with innovative clinical trials. The goal of the Geriatric Oncology program is to develop translational and clinical research in the interaction of cancer and aging. Ongoing research initiatives include geriatric cancer pharmacology and health outcomes research. The goal of the Health Outcomes research group is to provide high quality efficient healthcare by fostering interdisciplinary research in health economics, health policy outcome analysis, and health care delivery. Fellows completing the Clinical Scholars Program will be well trained to expedite translational research, perform innovative hypothesis-driven clinical research, and manage all phases of clinical trial research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of South Florida
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Yanamandra, Niranjan; Buzzeo, Robert W; Gabriel, Mark et al. (2011) Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther 337:636-43
Pidala, J; Kim, J; Perkins, J et al. (2010) Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant 45:919-24
Soliman, Hatem; Ferrari, Andrea; Thomas, David (2009) Sarcoma in the young adult population: an international view. Semin Oncol 36:227-36
Pidala, Joseph; Kim, Jongphil; Field, Teresa et al. (2009) Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 15:1116-21
Matsushita, Norimasa; Pilon-Thomas, Shari A; Martin, Lisa M et al. (2008) Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 333:167-79
Pilon-Thomas, Shari; Li, Wenbin; Briggs, Jon J et al. (2006) Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29:381-7
Yanamandra, Niranjan; Colaco, Nandita M; Parquet, Nancy A et al. (2006) Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 12:591-9
Buzzeo, Robert; Enkemann, Steven; Nimmanapalli, Rama et al. (2005) Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 11:6057-64